ICER Says Amgen/Novartis Migraine Drug Aimovig Is Cost Effective At $5,000 Net Price
Amgen said when Aimovig was approved that its $6,900 list price was designed to make sure a lot of patients could access the migraine prophylaxis. ICER now says that's a reasonable price, assuming a $5,000 net cost for the CGRP inhibitor, but only for patients who have failed on other treatments.
You may also be interested in...
The cost-effectiveness watchdog is worried about the cost of Novartis's once-monthly first-in-class migraine drug and is not convinced it is more effective than Allergan’s Botox, which can require up to 40 injections into the head and neck.
New commercial head Murdo Gordon described Aimovig as one of the best launches he's ever seen and said growth should continue – though moderate – based on prescriber experience and rapid transitions from free drug to reimbursed prescriptions.
The US FDA approved Teva's fremanezumab dosed monthly and quarterly versus Amgen's monthly Aimovig, and will launch at the same price. However, it's packaged as a pre-filled syringe instead of an autoinjector, has a higher rate of injection site reactions and it may launch alongside Lilly's Emgality.